Zeo ScientifiX (ZEOX) awards CSO 50,000 restricted common shares
Rhea-AI Filing Summary
Zeo ScientifiX, Inc. reported the initial holdings of its Chief Science Officer, David John Kisiday, in a Form 3. He beneficially owns 50,000 shares of common stock, all in the form of restricted stock granted on January 23, 2026 under the company’s 2021 Equity Incentive Plan.
The grant vests over two years, with 20,000 shares vesting on the first anniversary of Mr. Kisiday’s employment agreement effective January 23, 2026 and 30,000 shares vesting on the second anniversary. Vesting is contingent on his continued service and the other terms of the incentive plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Kisiday John David
Role
Chief Science Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock, $0.001 par value | -- | -- | -- |
Holdings After Transaction:
Common Stock, $0.001 par value — 50,000 shares (Direct)
Footnotes (1)
- F1. Represents shares of restricted common stock granted to the Reporting Person on January 23, 2026 under the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The shares vest as to 20,000 shares on the first anniversary of the Reporting Person's employment agreement with the Issuer effective January 23, 2026 (the "Employment Agreement") and 30,000 shares on the second anniversary of the Employment Agreement, subject to the Reporting Person's continued service with the Issuer and the other terms and conditions of the Incentive Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Zeo ScientifiX (ZEOX) Form 3 filing disclose?
The Form 3 shows Chief Science Officer David John Kisiday beneficially owning 50,000 shares of Zeo ScientifiX common stock. These shares are restricted stock granted under the 2021 Equity Incentive Plan with a two-year service-based vesting schedule tied to his employment agreement.
Is the ownership reported in the Zeo ScientifiX (ZEOX) Form 3 direct or indirect?
The Form 3 shows that the 50,000 shares of Zeo ScientifiX common stock are held with direct beneficial ownership. The filing lists the ownership form as “D,” indicating the shares are attributed directly to Chief Science Officer David John Kisiday rather than through an intermediary entity.